Hygieia, founded with a mission to enhance and simplify insulin therapy, focuses on developing innovative diabetes management solutions. Their core product, the d-Nav® Insulin Guidance System, provides personalized insulin dosage recommendations based on real-time blood glucose patterns. This system replaces traditional glucose meters and offers tailored dose adjustments between physician visits, aiming to improve diabetes control for insulin users. Hygieia targets the diabetes care market, seeking to make insulin therapy safer, more accurate, and more effective.

Notable individuals affiliated with Hygieia include healthcare professionals and technology experts dedicated to advancing diabetes care. The company has attracted significant investment from health-focused venture capital firms. Key achievements include the successful deployment of the d-Nav® system in various clinical settings, demonstrating improved patient outcomes and higher satisfaction rates. Hygieia's impact lies in transforming insulin therapy, thereby enhancing the quality of life for people with diabetes through better management and control.